Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Genelux Corporation Common Stock
GNLXCurrent price
2.94 USD
+0.14 USD (+5.00%)
Last closed
2.96 USD
Company
–
ISIN
US36870H1032
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
101 189 016 USD
Yield for 12 month
-78.19 %
1Y
3Y
5Y
10Y
15Y
GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California. Address: 2625 Townsgate Road, Westlake Village, CA, United States, 91361
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18.8 USDP/E ratio
–Dividend Yield
–Current Year
+170 000 USD
Last Year
+11 068 000 USD
Current Quarter
–
Last Quarter
+8 000 USD
Current Year
-848 000 USD
Last Year
+10 100 000 USD
Current Quarter
-204 000 USD
Last Quarter
-240 000 USD
Key Figures GNLX
1 year
3 years
5 years
10 years
EBITDA
-26 965 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-44.61 %
PEG Ratio
–
Return On Equity TTM
-88.57 %
Wall Street Target Price
18.8 USD
Revenue TTM
8 000 USD
Book Value
1.11 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-95.3 %
Dividend Yield
–
Gross Profit TTM
11 068 000 USD
Earnings per share
-0.95 USD
Diluted Eps TTM
-0.95 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GNLX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GNLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation GNLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8590.4831
Price Sales TTM
12648.627
Enterprise Value EBITDA
-327.1931
Price Book MRQ
2.6588
Financials GNLX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GNLX
For 52 weeks
1.6 USD
16.6 USD
50 Day MA
2.61 USD
Shares Short Prior Month
1 118 774
200 Day MA
3.85 USD
Short Ratio
8.36
Shares Short
1 039 627
Short Percent
3.57 %
BeatStart